Transition probabilities and predictors of adherence in a California medicaid population using antihypertensive and lipid-lowering medications

Value in Health

Volumn 12, Issue 4, 2009, Pages 544-550

  Nichol, Michael B ^a,b   Knight, Tara K ^b   Wu, Joanne ^b   Tang, Simon S K ^c   Cherry, Spencer B ^d   Benner, Joshua S ^d   Hussein, Mohamed ^d  

^a University of Southern California ^*  (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c PFIZER INC   (United States)

^d IMS Consulting   (United States)

Author keywords

Adherence; Antihypertensive medications; California Medicaid; Lipid lowering medications; Transition probabilities

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; THIAZIDE DIURETIC AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PATIENT COMPLIANCE; POPULATION RESEARCH; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

AGED; ANTIHYPERTENSIVE AGENTS; CALIFORNIA; DATA COLLECTION; DATABASES, FACTUAL; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; LOGISTIC MODELS; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PRESCRIPTION DRUGS; PROBABILITY; RISK ASSESSMENT; TIME FACTORS; UNITED STATES;

EID: 66249098503     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00474.x     Document Type: Article

References (28)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007 115 : e69 171.
2. Eaton CB, Feldman HA, Assaf AR, et al. Prevalence of hypertension, dyslipidemia, and dyslipidemic hypertension. J Fam Pract 1994 38 : 17 23. (Pubitemid 24027974)
3. Kostis JB. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther 2007 21 : 297 309. (Pubitemid 47387466)
4. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 361 : 1149 58.
5. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
6. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992 152 : 56 64.
7. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991 338 : 1281 5.
8. Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002 23 : 528 35.
9. Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in the treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995 311 : 293 95.
10. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations: should we target patients with the most to gain? J Gen Intern Med 2004 19 : 638 45.
11. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002 288 : 462 7.
12. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002 288 : 455 61.
13. Abughosh S, Kogut SJ, Andrade SE, et al. Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm 2004 10 : 404 11.
14. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005 165 : 1147 52.
15. Caspard H, Chan AK, Walker AM. Compliance with statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005 27 : 1639 46.
16. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999 37 : 846 57.
17. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997 50 : 105 16.
18. Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004 12 : 2800 5.
19. Hughes D, Cowell W, Koncz T, Cramer J. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007 10 : 498 509. (Pubitemid 350013268)
20. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2006 10 : 3 12.
21. Johnson ES, Mozaffari E. Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am J Manag Care 2002 8 (Suppl. 10 S249 54.
22. Rubenfire M. Safety and compliance with once-daily niacin extended release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol 2004 94 : 306 11.
23. Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am J Manag Care 1999 5 : 437 44.
24. Barnett E, Casper MI, Halverson JA, et al. Men and Heart Disease: An Atlas of Racial and Ethnic Disparities in Mortality First Edition. Morgantown, WV : Office for Social Environmental and Health Research, West Virginia University, 2001. ISBN 0-9665085-2-1.
25. Smedley BD, Stith AY, Nelson AR. Institute of Medicine (U.S.) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care: Unequal Treatment Confronting Racial and Ethnic Disparities in Health Care. Washington, DC : National Academy Press, 2002.
26. Eisert S, Gabow P. Effect of child health insurance plan enrollment on the utilization of health care services by children using a public safety net system. Pediatrics 2002 110 : 940 5.
27. Salganicoff A, Wyn R. Access to care for low-income women: the impact of Medicaid. J Health Care Poor Underserved 1999 10 : 453 67.
28. Taira DA, Iwane KA, Chung RS. Prescription drugs: elderly enrollee reports of financial access, receipt of free samples, and discussion of generic equivalents related to type of coverage. Am J Manag Care 2003 9 : 305 12.